Sign inJoin waitlistJoin the waitlist

Lisa Niswander

Clinical Assistant Professor · University at Buffalo School of Medicine

Credentials: · · · ·

History

University at Buffalo School of Medicine
Present

Pediatric Hematology Oncology
Children's Hospital of Philadelphia
2019–2022
Pediatrics
Children's Hospital of Philadelphia
2016–2018
University of Rochester School of Medicine and Dentistry
2012–2016

Research

Mutation in mouse hei10, an e3 ubiquitin ligase, disrupts meiotic crossing over
PLoS Genetics · 2007 · 106 citations
Systematic preclinical evaluation of CD33-directed chimeric antigen receptor T cell immunotherapy for acute myeloid leukemia defines optimized construct design
Journal for ImmunoTherapy of Cancer · 2021 · 62 citations
SDF-1 dynamically mediates megakaryocyte niche occupancy and thrombopoiesis at steady state and following radiation injury
Blood · 2014 · First of 5 authors · 59 citations

Sarah Tasian
6 papers
James Palis
4 papers
Terry Fry
3 papers
Caroline Diorio
1 paper
David Byrwa
1 paper · 1 as a fellow
David Korones
1 paper
Dekker Deacon
1 paper
John Kennedy
1 paper · 1 as a fellow
Kara Kelly
1 paper
Karen Rabin
1 paper
Laura Calvi
1 paper
LY
Lila Yang
1 paper

Grants

Leveraging Small Molecule Inhibitors to Improve CD19 CAR T Cell Immunotherapy for KMT2A-Rearranged ALL
National Cancer Institute · K08
Contact PI · $588.3K · Roswell Park Cancer Institute Corp
2024–2029
Microenvironmental Regulation of Megakaryopoiesis and Thrombopoiesis by SDF1
National Institute of Diabetes and Digestive and Kidney Diseases · F30
Contact PI · $137.8K · University of Rochester
2013–2017

Clinical trials

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2025–2028
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2025–2030